 |
(Photo= Yonhap news) |
[Alpha Biz= Reporter Kim Jisun] Lotte Biologics announced on the 11th that it will participate in six major global conferences across the U.S., Asia, and Europe in the second half of this year to boost its contract development and manufacturing organization (CDMO) business.
From September 23 to 26, the company will attend the "BioProcess International (BPI)" conference in Boston, USA. This event, focused on biopharmaceutical development and manufacturing, gathers over 250 companies from 40 countries annually. This year, nine conferences will be held, covering topics such as cell line development, cell culture, and manufacturing strategies.
Lotte Biologics plans to set up promotional booths at these events, showcasing its capabilities at the Incheon Songdo Bio Campus and its Antibody Drug Conjugate (ADC) services at the Syracuse Bio Campus in New York. The company aims to establish global partnerships by highlighting its advanced product manufacturing technology.
Additionally, Lotte Biologics will participate in other prestigious events such as "BIO-Europe," "Bio Japan," "CPHI 2024," and "Biomanufacturing World Summit (BMWS) 2024." The company is also focused on strengthening business cooperation with companies in Asia and identifying potential clients in the region through these conferences.
Earlier, Lotte Biologics participated in China's largest bio-industry conference, the "China Bio Partnering Forum," held in Shanghai on September 10-11.
Alphabiz Reporter Kim Jisun(stockmk2020@alphabiz.co.kr)
